183 related articles for article (PubMed ID: 18195574)
1. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
[No Abstract] [Full Text] [Related]
2. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
[TBL] [Abstract][Full Text] [Related]
3. Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Picchio G; De Meyer S; de Béthune MP
AIDS; 2008 Jan; 22(1):165-7. PubMed ID: 18090413
[No Abstract] [Full Text] [Related]
4. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
[No Abstract] [Full Text] [Related]
5. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
6. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
7. Fosamprenavir calcium plus ritonavir for HIV infection.
Torres HA; Arduino RC
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
[TBL] [Abstract][Full Text] [Related]
8. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
[TBL] [Abstract][Full Text] [Related]
9. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
10. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
11. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
Paulsen D; Elston R; Snowden W; Tisdale M; Ross L
J Antimicrob Chemother; 2003 Sep; 52(3):319-23. PubMed ID: 12917233
[No Abstract] [Full Text] [Related]
13. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Hill A; Marcelin AG; Calvez V
HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
[TBL] [Abstract][Full Text] [Related]
15. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
16. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
18. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
